We are live on
!
Find out more
FCM
Farallon Capital Management Portfolio holdings
AUM
$17.5B
1-Year Est. Return
50.95%
This Fund
S&P 500
This Quarter
Est. Return
+3.67%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$22.8B
AUM Growth
-$4.8M
(-0.02%)
Cap. Flow
+$69.6M
Cap. Flow
% of AUM
0.31%
Top 10 Holdings %
Top 10 Hldgs %
39.53%
Holding
188
New
24
Increased
37
Reduced
34
Closed
37
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DFS
Discover Financial Services
DFS
|
+$580M |
| 2 |
Autodesk
ADSK
|
+$544M |
| 3 |
McKesson
MCK
|
+$342M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$288M |
| 5 |
iShares Bitcoin Trust
IBIT
|
+$275M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTLT
CATALENT, INC.
CTLT
|
+$508M |
| 2 |
Salesforce
CRM
|
+$266M |
| 3 |
ServiceNow
NOW
|
+$264M |
| 4 |
S&P Global
SPGI
|
+$246M |
| 5 |
Sherwin-Williams
SHW
|
+$212M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.98% |
| 2 | Technology | 14.71% |
| 3 | Financials | 12.17% |
| 4 | Communication Services | 7.05% |
| 5 | Industrials | 4.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Glaukos
GKOS
$10.6B
| $390K | ﹤0.01% |
2,600
| – | – |
|
102
BrightSpring Health Services
BTSG
$12.4B
| $375K | ﹤0.01% |
22,000
| – | – |
|
103
Arcutis Biotherapeutics
ARQT
$3.18B
| $362K | ﹤0.01% |
26,000
| – | – |
|
104
Twist Bioscience
TWST
$7.25B
| $355K | ﹤0.01% |
7,650
-333,000
| -98% | -$15M |
|
105
United Therapeutics
UTHR
$23.1B
| $353K | ﹤0.01% |
1,000
| – | – |
|
|
BPMC
106
DELISTED
Blueprint Medicines
BPMC
| $349K | ﹤0.01% |
4,000
| – | – |
|
107
Axsome Therapeutics
AXSM
$10.9B
| $338K | ﹤0.01% |
4,000
| – | – |
|
108
Krystal Biotech
KRYS
$9.66B
| $313K | ﹤0.01% |
2,000
| – | – |
|
109
Progyny
PGNY
$2.2B
| $311K | ﹤0.01% |
18,000
-913,307
| -98% | -$14.2M |
|
|
ACLX
110
DELISTED
Arcellx
ACLX
| $307K | ﹤0.01% |
4,000
| – | – |
|
111
Scholar Rock
SRRK
$6.44B
| $303K | ﹤0.01% |
+7,000
| New | +$228K |
|
112
HCA Healthcare
HCA
$89.5B
| $300K | ﹤0.01% |
1,000
| – | – |
|
113
Globus Medical
GMED
$11.2B
| $298K | ﹤0.01% |
3,600
| – | – |
|
114
Immunovant
IMVT
$8.25B
| $297K | ﹤0.01% |
12,000
| – | – |
|
115
Bruker
BRKR
$8.14B
| $293K | ﹤0.01% |
5,000
-27,000
| -84% | -$1.6M |
|
116
Merit Medical Systems
MMSI
$5.32B
| $290K | ﹤0.01% |
3,000
| – | – |
|
117
HealthEquity
HQY
$8.75B
| $269K | ﹤0.01% |
2,800
| – | – |
|
118
Pacific Biosciences
PACB
$370M
| $247K | ﹤0.01% |
135,000
| – | – |
|
119
Sabra Healthcare REIT
SBRA
$5.37B
| $242K | ﹤0.01% |
14,000
| – | – |
|
|
SAGE
120
DELISTED
Sage Therapeutics
SAGE
| $232K | ﹤0.01% |
42,800
| – | – |
|
121
Cencora
COR
$61.2B
| $225K | ﹤0.01% |
1,000
-234,200
| -100% | -$55.1M |
|
122
Edwards Lifesciences
EW
$51.7B
| $222K | ﹤0.01% |
+3,000
| New | +$210K |
|
123
ICU Medical
ICUI
$4.61B
| $217K | ﹤0.01% |
1,400
| – | – |
|
124
Chemed
CHE
$7.22B
| $212K | ﹤0.01% |
400
| – | – |
|
125
Icon
ICLR
$12.7B
| $210K | ﹤0.01% |
1,000
-219,800
| -100% | -$51.3M |
|
Similar funds
BBA
MCM
LA
CM
ASRS
PP
VMPIC
HNB
Farallon Capital Management's Q4 2024 Portfolio in Review
As of Q4 2024, Farallon Capital Management held 188 positions worth $22.8B, down 0.02% from $22.8B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Farallon Capital Management's Q4 2024 filing shows 24 new, 37 increased, 34 reduced and 37 closed positions. Its largest new stake was Autodesk: 1,841,800 shares worth $544M. The largest sale was CATALENT, INC., an estimated $508M.
By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 32% a quarter earlier, followed by Technology and Financials.
- Farallon Capital Management's largest Q4 2024 buy was Autodesk: 1,841,800 shares worth $544M.
- Farallon Capital Management added most to Discover Financial Services in Q4 2024, an estimated $580M increase.
- Farallon Capital Management's biggest Q4 2024 reduction was Salesforce, cutting an estimated $266M.
- Farallon Capital Management fully exited CATALENT, INC. in Q4 2024, selling an estimated $508M.
- Farallon Capital Management's ten largest holdings make up 40% of its $22.8B portfolio in Q4 2024.
- Farallon Capital Management opened 24 new positions and closed 37 in Q4 2024.
- Farallon Capital Management's portfolio value fell 0.02% quarter-over-quarter to $22.8B.
Based on Farallon Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.